Granocyte

Granocyte is a prescription medication that contains the active ingredient lenograstim, supplied as a sterile solution for intravenous or subcutaneous administration. It belongs to the granulocyte colony‑stimulating factor (G‑CSF) analog class and is used in the European market to support patients with certain hematologic conditions. Lenograstim works by stimulating the production and function of neutrophils, helping to reduce the risk of infection during treatment‑related myelosuppression.

Granocyte is indicated for several clinical situations where neutrophil recovery is needed. It is commonly prescribed to manage neutropenia associated with cancer therapy and to aid stem‑cell collection procedures.

- Prevention and treatment of chemotherapy‑induced neutropenia - Support of myelosuppression after bone‑marrow transplantation - Mobilization of peripheral blood progenitor cells for autologous stem‑cell harvest - Adjunct therapy in patients with severe chronic neutropenia - Facilitation of hematopoietic recovery following high‑dose chemotherapy

Side effects of Granocyte vary in frequency and severity. Most patients experience mild, transient reactions, while serious events are less common but require medical attention.

Common: - Bone pain, especially in the hips or sternum - Mild fever or chills - Injection‑site erythema or irritation - Headache or fatigue - Nausea or mild gastrointestinal discomfort

Serious: - Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty - Splenic rupture or enlargement causing abdominal pain - Acute respiratory distress syndrome (ARDS) - Uncontrolled leukocytosis leading to vascular complications - Thromboembolic events such as deep‑vein thrombosis

Before initiating Granocyte therapy, clinicians should evaluate patient history and monitor for potential risks. Specific considerations include: - Known hypersensitivity to lenograstim or any formulation components - Pre‑existing splenomegaly or history of splenic injury - Active infections, particularly uncontrolled bacterial or fungal infections - Recent use of other hematopoietic growth factors or chemotherapy agents - Pregnancy or breastfeeding status, as safety data are limited - Renal or hepatic impairment may require dose adjustment or closer monitoring

Granocyte may interact with other medications, influencing its efficacy or safety profile. Awareness of these interactions helps optimize patient care.

Avoid: - Concurrent use of other G‑CSF products, which can increase the risk of severe leukocytosis - Live vaccines during treatment, due to potential alteration of immune response

Use with caution: - Corticosteroids, which may mask signs of infection - Anticoagulants, as elevated white‑cell counts can affect coagulation parameters - Chemotherapeutic agents that cause profound myelosuppression, requiring coordinated timing